The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease
- PMID: 22027014
- PMCID: PMC4118466
- DOI: 10.3233/JAD-2011-110824
The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease
Abstract
Rare mutations in AβPP, PSEN1, and PSEN2 cause uncommon early onset forms of Alzheimer's disease (AD), and common variants in MAPT are associated with risk of other neurodegenerative disorders. We sought to establish whether common genetic variation in these genes confer risk to the common form of AD which occurs later in life (>65 years). We therefore tested single-nucleotide polymorphisms at these loci for association with late-onset AD (LOAD) in a large case-control sample consisting of 3,940 cases and 13,373 controls. Single-marker analysis did not identify any variants that reached genome-wide significance, a result which is supported by other recent genome-wide association studies. However, we did observe a significant association at the MAPT locus using a gene-wide approach (p = 0.009). We also observed suggestive association between AD and the marker rs9468, which defines the H1 haplotype, an extended haplotype that spans the MAPT gene and has previously been implicated in other neurodegenerative disorders including Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration. In summary common variants at AβPP, PSEN1, and PSEN2 and MAPT are unlikely to make strong contributions to susceptibility for LOAD. However, the gene-wide effect observed at MAPT indicates a possible contribution to disease risk which requires further study.
References
-
- Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer’s disease. Neuroscience. 2001;105:99–107. - PubMed
-
- Zetzsche T, Rujescu D, Hardy J, Hampel H. Advances and perspectives from genetic research: Development of biological markers in Alzheimer’s disease. Expert Rev Mol Diagn. 2010;10:667–690. - PubMed
-
- Selkoe DJ. Alzheimer’s disease: Genes, proteins, and therapy. Physiol Rev. 2001;81:741–766. - PubMed
-
- Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, Lees AJ, Rossor MN, Quinn NP, Kertesz A, Khan MN, Hardy J, Lantos PL, St George-Hyslop P, Munoz DG, Mann D, Lang AE, Bergeron C, Bigio EH, Litvan I, Bhatia KP, Dickson D, Wood NW, Hutton M. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56:1702–1706. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- MC_U123160657/MRC_/Medical Research Council/United Kingdom
- G-0907/PUK_/Parkinson's UK/United Kingdom
- MC_U123160651/MRC_/Medical Research Council/United Kingdom
- G0701075/MRC_/Medical Research Council/United Kingdom
- G0902227/MRC_/Medical Research Council/United Kingdom
- G0900688/MRC_/Medical Research Council/United Kingdom
- G0601846/MRC_/Medical Research Council/United Kingdom
- G0700704/MRC_/Medical Research Council/United Kingdom
- BB/F019394/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- CSO_/Chief Scientist Office/United Kingdom
- 095317/WT_/Wellcome Trust/United Kingdom
- G0700704/84698/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- P01 AG003991/AG/NIA NIH HHS/United States
- P50 AG005681/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
